SCAI Stages Predict Cardiogenic Shock Risk 10/15/25

Welcome to Cardiology Today – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like nuclear imaging and transthyretin amyloid cardiomyopathy. Key takeaway: SCAI Stages Predict Cardiogenic Shock Risk. Article Links: Article 1: Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial. (ESC heart failure) Article 2: Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial. (ESC heart failure) Article 3: Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. (ESC heart failure) Article 4: Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. (ESC heart failure) Article 5: Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study. (ESC heart failure) Full episode page: https://podcast.explainheart.com/podcast/scai-stages-predict-cardiogenic-shock-risk-10-15-25/ Featured Articles Article 1: Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial. Journal: ESC heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41085472 Summary: The S.E.I.S.M.i.C. extension trial investigated the haemodynamic effects of istaroxime in S.C.A.I. stage B cardiogenic shock related to acute decompensated heart failure. Researchers randomized 30 patients to receive either placebo or istaroxime (0.5-1.0 micrograms per kilogram per minute) intravenously for 60 hours. This post-hoc analysis specifically assessed the impact of istaroxime on invasively obtained haemodynamic measures. The findings from this evaluation are crucial for understanding istaroxime’s potential role in managing cardiogenic shock and guiding future therapeutic paradigms. Article 2: Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial. Journal: ESC heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41083288 Summary: This sub-study of the E.C.L.S.-S.H.O.C.K. trial investigated the prognostic impact of S.C.A.I. shock severity classes in acute myocardial infarction-related cardiogenic shock. Researchers aimed to clarify how S.C.A.I. stages influence the effectiveness of extracorporeal life support therapy in these patients. The study establishes the critical role of S.C.A.I. classification for risk stratification in acute myocardial infarction complicated by cardiogenic shock. These findings provide a more nuanced understanding of prognosis and treatment response in this high-risk population, guiding personalized therapeutic approaches. Article 3: Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. Journal: ESC heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41081448 Summary: This study assessed the frequency of planar scintigraphy, with and without single-photon emission computed tomography, in hypertrophic cardiomyopathy patients screened for transthyretin amyloid cardiomyopathy in the T.T.R.A.C.K. study. It addressed variability in readings across different cardiac nuclear imaging tests, radiotracers, and readers, as well as discrepancies in echocardiographic findings. By evaluating these diagnostic methodologies, the research provides valuable insights into optimizing the identification of transthyretin amyloid cardiomyopathy. This work ultimately aims to reduce diagnostic delays, which significantly impact patient outcomes. Article 4: Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. Journal: ESC heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41078121 Summary: This retrospective cohort study evaluated the association of glucagon-like peptide-1 receptor agonist therapy with cardiovascular outcomes in patients with left ventricular assist devices. Left ventricular assist devices are vital for advanced heart failure, and obesity and diabetes are known to impact patient outcomes. By investigating the role of glucagon-like peptide-1 receptor agonists, which have demonstrated cardiovascular benefits, this research addresses a previously underexplored therapeutic area. The findings provide crucial information for optimizing medical management and potentially improving long-term outcomes for patients supported by left ventricular assist devices. Article 5: Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study. Journal: ESC heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41078081 Summary: The N.A.C.L.O.C.R.o.-H.F. study prospectively examined the trajectories of urinary chloride and urinary sodium during acute heart failure hospitalization in elderly patients with heart failure with preserved ejection fraction. The research aimed to clarify their comparative dynamics and association with fluid overload. By evaluating these potential biomarkers for decongestion, the study establishes a clearer understanding of their utility in monitoring fluid status. These findings are pivotal for refining therapeutic guidance and achieving more precise decongestion strategies in this complex patient population. Transcript Today’s date is October 15, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial. The S.E.I.S.M.i.C. extension trial investigated the haemodynamic effects of istaroxime in S.C.A.I. stage B cardiogenic shock related to acute decompensated heart failure. Researchers randomized 30 patients to receive either placebo or istaroxime (0.5-1.0 micrograms per kilogram per minute) intravenously for 60 hours. This post-hoc analysis specifically assessed the impact of istaroxime on invasively obtained haemodynamic measures. The findings from this evaluation are crucial for understanding istaroxime’s potential role in managing cardiogenic shock and guiding future therapeutic paradigms. Article number two. Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial. This sub-study of the E.C.L.S.-S.H.O.C.K. trial investigated the prognostic impact of S.C.A.I. shock severity classes in acute myocardial infarction-related cardiogenic shock. Researchers aimed to clarify how S.C.A.I. stages influence the effectiveness of extracorporeal life support therapy in these patients. The study establishes the critical role of S.C.A.I. classification for risk stratification in acute myocardial infarction complicated by cardiogenic shock. These findings provide a more nuanced understanding of prognosis and treatment response in this high-risk population, guiding personalized therapeutic approaches. Article number three. Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. This study assessed the frequency of planar scintigraphy, with and without single-photon emission computed tomography, in hypertrophic cardiomyopathy patients screened for transthyretin amyloid cardiomyopathy in the T.T.R.A.C.K. study. It addressed variability in readings across different cardiac nuclear imaging tests, radiotracers, and readers, as well as discrepancies in echocardiographic findings. By evaluating these diagnostic methodologies, the research provides valuable insights into optimizing the identification of transthyretin amyloid cardiomyopathy. This work ultimately aims to reduce diagnostic delays, which significantly impact patient outcomes. Article number four. Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. This retrospective cohort study evaluated the association of glucagon-like peptide-1 receptor agonist therapy with cardiovascular outcomes in patients with left ventricular assist devices. Left ventricular assist devices are vital for advanced heart failure, and obesity and diabetes are known to impact patient outcomes. By investigating the role of glucagon-like peptide-1 receptor agonists, which have demonstrated cardiovascular benefits, this research addresses a previously underexplored therapeutic area. The findings provide crucial information for optimizing medical management and potentially improving long-term outcomes for patients supported by left ventricular assist devices. Article number five. Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study. The N.A.C.L.O.C.R.o.-H.F. study prospectively examined the trajectories of urinary chloride and urinary sodium during acute heart failure hospitalization in elderly patients with heart failure with preserved ejection fraction. The research aimed to clarify their comparative dynamics and association with fluid overload. By evaluating these potential biomarkers for decongestion, the study establishes a clearer understanding of their utility in monitoring fluid status. These findings are pivotal for refining therapeutic guidance and achieving more precise decongestion strategies in this complex patient population. Thank you for listening. Don’t forget to subscribe. Keywords nuclear imaging, transthyretin amyloid cardiomyopathy, haemodynamics, echocardiography, decongestion, extracorporeal life support, heart failure with preserved ejection fraction, planar scintigraphy, prognosis, acute heart failure, acute decompensated heart failure, S.C.A.I. stage B, cardiogenic shock, hypertrophic cardiomyopathy, istaroxime, S.C.A.I. classification, heart failure, acute myocardial infarction, urinary chloride, left ventricular assist devices, cardiovascular outcomes, urinary sodium, fluid overload, glucagon-like peptide-1 receptor agonists. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post SCAI Stages Predict Cardiogenic Shock Risk 10/15/25 first appeared on Cardiology Today.